Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune

November 23, 2004

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

On November 12 the U.S. Food and Drug Administration's AIDS listserve noted a "Dear Doctor" letter from Bristol-Myers Squibb, warning that the two particular three-drug combinations noted above had shown a high rate of virologic failure in treatment-naive patients with high viral loads (about half of those patients failed the treatment). The problem seems to be specific to these regimens, as Sustiva has worked with Viread-based regimens, and with Videx-based regimens, in different trials.

The FDA email is available on its archive, www.fda.gov/oashi/aids/listserve/listserve2004.html (you need to scroll down or use a search in your browser). And this page has the full BMS "Dear Doctor" letter attached.


Comment

There are now several antiretroviral regimens that failed to control the virus, and were not predicted to fail on the basis of clinical trials, physicians' experience, and known drug interactions. The leading theory seems to be that the bad combinations have a genetic barrier against the virus that is too low. If so, then it may be possible to better predict such failures from existing resistance data -- and perhaps to improve other regimens as well, by avoiding possible weaknesses that are less serious but still important. Has anybody yet brought this information together into a model that works?


ISSN # 1052-4207

Advertisement
Copyright 2004 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
 
See Also
HIV Medications: When to Start and What to Take -- A Guide From TheBody.com
More Research on First-Line HIV Treatment
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement